

# Neurology

## Board of Editors

### EDITOR-IN-CHIEF

Lewis P. Rowland, MD, *New York, NY*

### FOUNDING EDITOR-IN-CHIEF

Russell N. DeJong, MD, *Ann Arbor, MI*

### ASSOCIATE EDITOR

Stanley Fahn, MD, *New York, NY*

### EDITORIAL BOARD

Louis R. Caplan, MD, *Chicago, IL*

Robert A. Fishman, MD, *San Francisco, CA*

Myron D. Ginsberg, MD, *Miami, FL*

Nicholas K. Gonatas, MD, *Philadelphia, PA*

Robert J. Gummit, MD, *Minneapolis, MN*

Kenneth M. Heilman, MD, *Gainesville, FL*

Jun Kimura, MD, *Iowa City, IA*

John F. Kurtzke, MD, *Washington, DC*

Robert P. Lisak, MD, *Philadelphia, PA*

Hugo W. Moser, MD, *Baltimore, MD*

Karin B. Nelson, MD, *Bethesda, MD*

David A. Stumpf, MD, *Denver, CO*

B. Todd Troost, MD, *Winston-Salem, NC*

Leslie P. Weiner, MD, *Los Angeles, CA*

B. J. Wilder, MD, *Gainesville, FL*

### EDITOR-IN-CHIEF'S OFFICE

Shirley Susarchick, *Editorial Assistant*

### NEWSLETTER STAFF

John Conomy, MD, *Editor, Rosalie Burns, MD,*

Patrick Sweeney, MD, *Jack Whisnant, MD,*

Carolyn Carwell, *Associate Editors*

### OFFICERS

Nelson G. Richards, MD, *President*

Melvin Greer, MD, *President-Elect*

John Conomy, MD, *First Vice-President*

Rosalie A. Burns, MD, *Second Vice-President*

Lawrence D. Jacobs, MD, *Secretary-Treasurer*

William H. Jeffreys, MD, *Asst. Secretary-Treasurer*

### EXECUTIVE OFFICE

#### AMERICAN ACADEMY OF NEUROLOGY

Jan W. Kolehmainen, *Executive Director*

2221 University Ave. S.E., Mpls., MN 55414 (612-623-8115)

### Publication Staff

Bernard J. Rogers, *Publisher/President*

Bruce Millar, *Executive Editor*

Peter G. Studer, *Editor*

Anne Rossi, *Managing Editor*

Charles Rosenberg, *Chief Copy Editor*

Laura Monroe,

Carol Vaughn, and

Jody Krasner, *Copy Editors*

Louise Burger, *Editorial Adm. Assistant*

Carol Morris, *Editorial Adm. Assistant*

Dorothea Hart, *Production Manager*

Bonnie Ling, *Production Supervisor*

Joan Holmes, *Editorial Production*

Joyce Polo, *Circulation Supervisor*

Linda Winick, *Promotion Director*

David Komitau, *Graphics Coordinator*

Jon Dallman, *Graphics Director*

### HARCOURT BRACE JOVANOVIĆ PUBLICATIONS

Robert L. Edgell, *Chairman*

Richard Moeller, *President*

Arland Hirman, *Treasurer*

Lars Fladmark, *Executive Vice President*

Joe Bilderbach, *Vice President*

James Gherna, *Vice President*

George A. Glenn, *Vice President*

Harry Ramaley, *Vice President*

## Information for Authors

NEUROLOGY, the official publication of the American Academy of Neurology, publishes clinical and research articles in neurology and related fields.

### Manuscripts should be submitted to:

Lewis P. Rowland, MD

Editor-in-Chief, NEUROLOGY

Neurological Institute

710 West 168th Street

New York, NY 10032

**Manuscripts** should be contributed solely to NEUROLOGY. Papers read at Academy meetings are the property of the Academy and should be submitted to the Editor-in-Chief. Authors who wish to publish them elsewhere should request release first. Authors are asked to include their telephone numbers with their submitted manuscripts.

Our fully computerized system can electronically "read" your manuscript into our computer, thus eliminating the keyboarding step and allowing even faster and more efficient processing. This can be accomplished effectively only if these guidelines are followed: Please type your original manuscript with one of the following typewriter elements: OCR-B (preferred), Prestige Pica, Courier 10, Courier 12, Prestige Elite, Pica, Letter Gothic, or Elite. Comply with the pitch listed on the individual typing element. In addition, the manuscript should be the original (not a photocopy), typed with good quality ribbons on 8½" × 11" or 8½" × 14" bond paper. The left margin should equal ½", and the right margin ½" or more. Paragraph indents should be 4 spaces or more. All corrections should be whited out and retyped.

Manuscripts should (1) be submitted in triplicate, (2) be typed double-spaced, and (3) contain an abstract of less than 100 words that will eliminate the need for a summary. Short articles (six double spaced pages) may be submitted as **Brief Communications**. Computer-generated galley proofs will be sent to authors for correction. A schedule of charges for reprints will be mailed at the time of publication.

Authors should refer to the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" for detailed style guidelines. Copies can be obtained by sending a stamped self-addressed #10 envelope to:

NEUROLOGY

Style Guide

7500 Old Oak Boulevard

Cleveland, OH 44130

**Illustrations** (unmounted glossies) should be of quality for reproduction and be submitted in triplicate. The back should carry the paper title and indicate the top side; figure captions should be indicated on a separate page. A copy of permission statement is needed when faces show in a photograph. Color figures may be submitted, but the author must bear part of the expense for color reproductions. The cost will be estimated on an individual basis.

**Tables** should be typed on separate sheets.

**References** should be cited in numerical order in the text, designated by superscript numbers, and listed at the end of the paper in numerical sequence. All authors should be listed when there are six or less; when there are seven or more, list only the first three and add "et al." References should be typed in the following manner.

#### Journal reference:

1. Lefvert AK, Osterman PO. Newborn infants to myasthenic mothers: a clinical study and an investigation of acetylcholine receptor antibodies in 17 children. *Neurology (Cleveland)* 1983;33:133-8.

#### Textbook reference:

2. Moossy J. Vascular diseases of the spinal cord (chap 34). In: Baker AB, Baker LH, eds. *Clinical neurology*, vol 3. Hagerstown MD: Harper & Row, 1976:1-10.

Abbreviations of journal names are given in *Index Medicus*.

**Mathematic formulas** and equations that occupy more than 1 line of type should be avoided.

**Letters to the Editor** are welcome. They should be limited to two double-spaced pages.

**Books for review** should be sent to:

Stanley Fahn, MD

Associate Editor, NEUROLOGY

Neurological Institute

710 West 168th Street

New York, NY 10032

**Business correspondence** should be addressed to:

NEUROLOGY

7500 Old Oak Boulevard

Cleveland, OH 44130

## **Reye's syndrome and short-chain fatty acids**

**To the Editor:** In measured plasma levels of short-chain fatty acids in Reye's syndrome, McArthur et al<sup>1</sup> found a significant increase only of propionic acid levels in patients with moderate or severe clinical signs, and of isovaleric acid concentrations in patients with moderate signs; isobutyric, n-butyric, n-valeric and caproic acid concentrations showed no elevation, but tended to values lower than those of controls. Of these six acids, increased levels of only isovaleric and propionic acids occur in disorders of biotin-dependent carboxylases. Isovaleric acid is elevated in cases of diminished activity of 3-methylcrotonyl-CoA carboxylase; propionic acid is elevated in propionyl-CoA carboxylase deficiency.<sup>2</sup> The most prominent finding<sup>3</sup> in a postmortem examination of mitochondrial liver enzymes in patients with Reye's syndrome was reduction of pyruvate carboxylase activity, another biotin-dependent carboxylase, and this could explain the lactic acidemia of Reye's syndrome.<sup>1,4</sup> We found a marked reduction of plasma levels of biotin (caused by intake of anticonvulsants) and elevation of biotin-dependent short-chain fatty acids in the urine of seizure patients.<sup>5,6</sup> Because Reye's syndrome is sometimes a fatal complication of anticonvulsant therapy,<sup>7</sup> the possible relation between biotin status or biotin-dependent carboxylases should be considered in investigations of Reye's syndrome.

*Klaus-Henning Krause, MD  
Peter Berlit, MD  
Heidelberg, F.R.G.*

*Jean-Pierre Bonjour, PhD  
Basle, Switzerland*

## **References**

1. McArthur B, Sarnaik AP, Mitchell RA. Short-chain fatty acids and encephalopathy of Reye's syndrome. *Neurology (Cleveland)* 1984;34:831-4.
2. Bonjour JP. Biotin-dependent enzymes in inborn errors of metabolism in humans. *World Rev Nutr Diet* 1981;38:1-88.
3. Robinson BH, Taylor J, Cutz E, Gall G. Reye's syndrome: preservation of mitochondrial enzymes in brain and muscle compared with liver. *Pediatr Res* 1978;12:1045-7.
4. Tonsgard JH, Huttenlocher PR, Thisted RA. Lactic acidemia in Reye's syndrome. *Pediatrics* 1982;69:64-9.

- 
5. Krause KH. Biotin-Erniedrigung unter antiepileptischer Behandlung: Ein Beitrag zur möglichen Wirkungsweise von Antikonvulsiva. Freiburg: Hochschul Verlag, 1983.
  6. Krause KH, Bonjour JP, Berlit P, Kochen W. Biotin status of epileptics. *Ann NY Acad Sci* 1984 (in press).
  7. Jeavons PM. Hepatotoxicity of antiepileptic drugs. In: Oxley J, Janz D, Meinardi H, eds. *Chronic toxicity of antiepileptic drugs*. New York: Raven Press, 1983:1-45.

**Reply from the Authors:** Krause, Berlit, and Bonjour offer an interesting explanation for the origin of short-chain fatty acidaemia in Reye's syndrome (RS). To our knowledge, plasma biotin levels have not been measured in Reye patients, and the possibility of drug-induced biotin deficiency cannot be excluded. Nevertheless, some clinical and biochemical findings seem to be inconsistent with this mechanism as the primary cause of Reye's syndrome.

Clinically manifest biotin deficiency is rare, reported with prolonged parenteral alimentation or excessive ingestion of raw egg white.<sup>1,2</sup> The typical manifestations (including seborrheic dermatitis, alopecia, and conjunctivitis) are slow to develop and respond promptly to biotin therapy. Conversely, Reye's encephalopathy is manifested by pernicious vomiting, behavior changes, and agitation that are sometimes followed by decorticate or decerebrate coma. Flaccid coma and death may result from brainstem compression due to intracranial hypertension.

Several chemical agents (including valproic acid) have been incriminated as causes of a "Reye-like syndrome." However, none of them has been documented as a cause of the salient ultrastructural, biochemical, and histochemical changes in liver that are characteristic of Reye's syndrome and which collectively define it as a distinct disease. In two patients with fatal hepatic failure after use of valproic acid, the liver injury differed from the lesion of RS on histopathologic examination.<sup>3</sup> Hepatic pyruvate carboxylase activity is decreased in RS, but the biotin-independent hepatic mitochondrial enzymes, such as glutamic dehydrogenase and monoamine oxidase, are also decreased.<sup>4</sup> These alterations are probably due to a general injury of hepatic mitochondria.

Given the fasted state of the RS patient before admission and the high rate of protein catabolism,<sup>5</sup> the relatively modest elevations of short-chain fatty acids would be expected.

*Robert A. Mitchell, PhD  
Brian McArthur, MS  
Ashok P. Sarnaik, MB, BS  
Detroit, MI*

## References

1. Mock DM, DeLorimer AA, Liebman WM, Sweetman L, Baker H. Biotin deficiency: an unusual complication of parenteral alimentation. *N Engl J Med* 1981;304:820-3.
2. Van Lancker JL. *Molecular and cellular mechanisms in disease*. New York: Springer-Verlag, 1976.
3. Suchy FJ, Balistreri WF, Buchino JJ, et al. Acute hepatic failure associated with the use of sodium valproate. *N Engl J Med* 1979;300:962-6.
4. Mitchell RA, Ram ML, Arcinue EL, Chang CH. Comparison of cytosolic and mitochondrial hepatic enzyme alterations in Reye's syndrome. *Pediatr Res* 1980;14:1216-21.
5. Snodgrass PJ, DeLong GR. Urea cycle enzyme deficiencies and an increased nitrogen load producing hyperammonemia in Reye's syndrome. *N Engl J Med* 1976;294:855-60.